[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597745":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":11,"armGroups":19,"interventions":30,"overallOfficials":11,"centralContacts":40,"locations":46,"responsibleParty":61,"collaborators":11,"id":65,"slug":11,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":11,"eligibilityCriteria":69,"healthyVolunteers":66,"sex":70,"minAge":71,"maxAge":11,"enrollmentInfo":72,"targetDuration":11,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":11,"overallStatus":81,"whyStopped":11,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Sichuan Cancer Hospital and Research Institute","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Objective response rate",null,"3 months",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"NON_RANDOMIZED","PARALLEL","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":11},"NONE",[20,25],{"label":21,"type":22,"description":11,"interventionNames":23},"Control Group","ACTIVE_COMPARATOR",[24],"Drug: Control: gemcitabine, cisplatin, tirelizumab",{"label":26,"type":27,"description":11,"interventionNames":28},"Experimental group","EXPERIMENTAL",[29],"Drug: Experimental: gemcitabine, cisplatin, tirelizumab and radiotherapy",[31,36],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":11},"DRUG","Control: gemcitabine, cisplatin, tirelizumab","PD-1 inhibitors combined with chemotherapy",[21],{"type":32,"name":37,"description":38,"armGroupLabels":39,"otherNames":11},"Experimental: gemcitabine, cisplatin, tirelizumab and radiotherapy","PD-1 inhibitors combined with chemoradiotherapy",[26],[41],{"name":42,"role":43,"phone":44,"phoneExt":11,"email":45},"Lu Li","CONTACT","13882258173","lilu_mm@163.com",[47],{"facility":5,"status":11,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Chengdu","Sichuan","610041","China","CN",{"type":54,"coordinates":55},"Point",[56,57],104.06667,30.66667,{"lat":57,"lon":56},[60],{"name":42,"role":43,"phone":44,"phoneExt":11,"email":45},{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Yangkun Luo","Director","100597745",false,"NCT07062484","A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. age of at least 18 years;\n2. Karnofsky Performance Status (KPS) ≥60;\n3. histologically confirmed nasopharyngeal squamous carcinoma;\n4. metastatic disease after primary standard treatment (patients who had metastatic diseases over six months after treatment);\n5. at least 1 measurable metastatic lesions in lung or mediastinal or pleura (imaging for distant metastases with FDG-PET\u002FCT or chest\u002Fabdomen CT with contrast);\n6. adequate renal , liver and bone marrow function.\n\nExclusion Criteria:\n\n1. previous treatment with an immune checkpoint inhibitor;\n2. recurrent disease;\n3. previous systemic chemotherapy for metastatic disease;\n4. symptomatic central nervous system metastases;\n5. a history of non-infectious pneumonitis that required glucocorticoids, or active autoimmune disease;\n6. severe organ dysfunction or not suitable for chemoradiotherapy;\n7. individuals that had serious kidney, heart, blood, nervous system, or liver diseases or psychiatric disorders;\n8. individuals that had taken part in any other clinical trials testing other drugs within 3 months of the present study;\n9. other patients whom researchers deemed unsuitable to participate in the study.","ALL","18 Years",{"count":73,"type":74},600,"ESTIMATED","INTERVENTIONAL",[77],"NA","This study is a retrospective real-world study. In this study, we plan to collect the clinical data of lung metastatic nasopharyngeal carcinoma patients who received PD-1 inhibitors and chemotherapy combined with or without radiotherapy.",[80],"Lung Metastatic Nasopharyngeal Carcinoma","NOT_YET_RECRUITING","2025-07-10",{"date":84,"type":85},"2025-07-14","ACTUAL",{"date":87,"type":74},"2025-07",{"date":89,"type":74},"2025-12",{"name":5,"class":6},1]